Predict your next investment

MOBILE & TELECOMMUNICATIONS | Mobile Commerce / Auto
myvinny.com

See what CB Insights has to offer

Stage

Debt | Alive

Total Raised

$300K

Last Raised

$300K | 8 yrs ago

About Green Sky Labs

Green Sky Labs is the developer of Vinny, a free and independent consumer-based app that reveals the dealer cost for used cars. Utilizing national car auction data and complex mathematical algorithms, Vinny lets shoppers use their smartphone to scan the VIN barcode on a used car they are interested in purchasing, but instead of displaying the retail price, Vinny calculates the wholesale price for that specific make and model based on a database of millions of actual transactions.

Green Sky Labs Headquarter Location

135 Ocean Parkway Suite 12T

Brooklyn, New York, 11218,

United States

201-394-7538

Latest Green Sky Labs News

Nurcapital Corporation Ltd. and Green Sky Labs Inc. Announce Signing of Definitive Agreement and Provide Update on Proposed Qualifying Transaction

Mar 19, 2021

By Reading Time: 5 minutes Toronto, Ontario–(Newsfile Corp. – March 19, 2021) – Nurcapital Corporation Ltd. (TSXV: NCL.H) (“Nurcapital” or the “Company“), a capital pool company, and Green Sky Labs Inc. (“GSL“), a private corporation incorporated under the Business Corporations Act (Alberta) (the “ABCA“), are pleased to announce today, further to a press release dated September 4, 2020, that they have executed a definitive business combination agreement (the “Definitive Agreement“) which, subject to certain conditions and applicable TSX Venture Exchange (“TSXV“) approval, will result in the reverse takeover of Nurcapital by GSL and will constitute Nurcapital’s “Qualifying Transaction”, as defined by Policy 2.4 – Capital Pool Companies (“Policy 2.4“) of the TSXV (the “Proposed Qualifying Transaction“). Definitive Agreement Pursuant to the Definitive Agreement, on closing of the Proposed Qualifying Transaction (“Closing“), it is expected that: Nurcapital will consolidate all of the then issued and outstanding common shares of Nurcapital (the “Nurcapital Common Shares“) resulting in the aggregate number of post-consolidation Nurcapital Common Shares multiplied by the Issue Price (as defined below) being equal to $1,190,000, subject to customary adjustments (the “Consolidation“); GSL and a wholly-owned subsidiary of Nurcapital, will be amalgamated under the ABCA (the “Amalgamation“) and continue as one corporation (“Amalco“), and Amalco will become a wholly-owned subsidiary of Nurcapital; Nurcapital will change its name to “Green Sky Labs Inc.” (on a post-Closing basis, the “Resulting Issuer“); and The holders of GSL common shares will receive one Nurcapital Common Share for each common share of GSL held by them, and the common shares of GSL will subsequently be cancelled. The Resulting Issuer’s business objective will be to carry on the business of GSL by engaging in technology incubation and commercialize disruptive technologies in the biotech and related industries through strategic partnerships, mergers and acquisitions as well as public offerings. The Closing of the Proposed Qualifying Transaction is expected to occur in Q2/Q3 2021. Update Regarding Proposed Qualifying Transaction The parties and their advisors continue to advance the audited, unaudited and pro forma financial statements of GSL and Nurcapital and are preparing a draft filing statement to be submitted (the “Filing Statement“) in accordance with the policies of the TSXV. It is a condition of the Definitive Agreement that GSL will complete a financing, which is expected to comprise a brokered private placement of securities of GSL to raise gross proceeds of a minimum of C$5 million (the “Concurrent Offering“). The price of the securities for the Concurrent Offering will be the lessor of (i) $1.35 per Nurcapital Common Share, (ii) if the Concurrent Offering is comprised of equity securities, the issue price of such equity securities, or (iii) if the Concurrent Offering is comprised of convertible debt, the conversion price of such convertible debt, less a discount of 25%, (the “Issue Price“). Further details of the Concurrent Offering will follow at a later date. Completion of the Proposed Qualifying Transaction is subject to a number of conditions, including closing of the Concurrent Offering, receipt of applicable regulatory approvals, including the approval of the TSXV for the Proposed Qualifying Transaction, completion of satisfactory due diligence and the execution of any transaction documents related to the Definitive Agreement. About Nurcapital Nurcapital was incorporated under the Business Corporations Act (Ontario) on January 8, 2015. The Company is listed as a capital pool company on the NEX Board of the TSXV. The Nurcapital Common Shares commenced trading on the TSXV on February 4, 2016 under the trading symbol “NCL.P”. In conjunction with Nurcapital’s transfer to the NEX on July 31, 2018, its trading symbol changed from “NCL.P” to “NCL.H”. Nurcapital’s business objective is to identify and evaluate assets or businesses with a view to a potential acquisition by completing a Qualifying Transaction (like the Proposed Qualifying Transaction). Trading in the Nurcapital Common Shares is currently halted pending completion of the Proposed Qualifying Transaction. About GSL GSL was incorporated on April 17, 2014 pursuant to the Business Corporations Act (Alberta). Since its inception, GSL has been a technology incubation company that has developed disruptive technologies in the biotech and related industries. GSL’s primary business objective is to commercialize these technologies through strategic partnerships, mergers and acquisitions as well as public offerings. GSL’s current holdings are comprised of majority or non-majority interests in the following five businesses: (a) My Next Health, a genomics-based digital therapeutics company which seeks to significantly enhance patient outcomes and reduce costs, including a genetics-based COVID-19 risk assessment application; (b) AGENTIX Biopharma Corp. (OTC:AGTX), a U.S. publicly-listed company developing pharmaceuticals and health solutions for patients and consumers using proprietary compounds and delivery systems that target the endocannabinoid system for therapeutic applications; (c) Nectar Health Sciences Inc., which owns a patent-pending technology to isolate cannabinoids at high levels of purity for pharmaceutical and nutraceutical applications; (d) Kalmex Inc., a joint venture corporation focused on the development of a cannabis extraction manufacturing facility using a proprietary membrane-based technology to produce full spectrum cannabinoid extracts; and (e) Trichome Agronomy Corp., a Manitoba-based industrial hemp cultivation company that has developed a multi-stage agronomy program capable of creating high-quality, conditioned hemp flower biomass on an industrial scale and also utilizing the whole hemp plant for derivative products. GSL Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Green Sky Labs Patents

Green Sky Labs has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/14/2015

Cannabinoids, Monoterpenes, Designer drugs, Flavors, Ketones

Application

Application Date

12/14/2015

Grant Date

Title

Related Topics

Cannabinoids, Monoterpenes, Designer drugs, Flavors, Ketones

Status

Application

Green Sky Labs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Green Sky Labs Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.